Literature DB >> 24877743

Acute renal failure and metformin-associated lactic acidosis following colonoscopy.

Mohammad I Hussain1, Bruce M Hall2, Barbara Depczynski3, Susan J Connor4.   

Abstract

Two patients with type 2 DM developed acute kidney injury and lactic acidosis following colonoscopy despite withholding metformin. We recommend that DM patients on metformin also withhold ACEI, ARB until their dehydration is reversed after colonoscopy. This should reduce the risk of acute renal failure (ARF) and of lactic acidosis. Crown
Copyright © 2014. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ACEI or ARB; Acute renal failure (ARF); Colonoscopy; Lactic acidosis; Metformin

Mesh:

Substances:

Year:  2014        PMID: 24877743     DOI: 10.1016/j.diabres.2013.12.055

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  4 in total

Review 1.  Antihyperglycemic therapy during colonoscopy preparation: A review and suggestions for practical recommendations.

Authors:  Irit Hochberg; Ori Segol; Rachel Shental; Pnina Shimoni; Roy Eldor
Journal:  United European Gastroenterol J       Date:  2019-04-20       Impact factor: 4.623

2.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

3.  Reduced Mortality Associated With the Use of Metformin Among Patients With Autoimmune Diseases.

Authors:  Chun-Yu Lin; Chun-Hsin Wu; Chung-Yuan Hsu; Tien-Hsing Chen; Ming-Shyan Lin; Yu-Sheng Lin; Yu-Jih Su
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

4.  Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study.

Authors:  Paul J Connelly; Mike Lonergan; Enrique Soto-Pedre; Louise Donnelly; Kaixin Zhou; Ewan R Pearson
Journal:  Diabetes Obes Metab       Date:  2017-07-05       Impact factor: 6.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.